Department of Anatomy, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Faculty of Medicine, Department of Infertility, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
J Assist Reprod Genet. 2019 Aug;36(8):1701-1712. doi: 10.1007/s10815-019-01461-6. Epub 2019 Jul 21.
Management options for PCOS, as the most prevalent endocrine disorder in women of reproductive age, using natural supplements have a high priority for physicians, especially based on the etiological pathways. Therefore, this study was conducted to describe the effect of resveratrol on the angiogenesis pathway, for management of PCOS through assessing VEGF, HIF1 gene expression, and laboratory parameters.
In this triple-blind RCT, PCOS was confirmed in ICSI candidates based on the Rotterdam criteria. Sixty-two patients that met the inclusion criteria were randomly assigned to two groups. All patients took resveratrol 800 mg/day or placebo for 40 days orally from the beginning of their previous menstruation cycle until the oocyte retrieval day. The serum levels of different hormones were measured, and the expression of HIF1 & VEGF genes was quantified by real-time PCR.
As for the laboratory hormone assay in 61 PCOS patients, a significant mean difference was seen in the FSH, LH, TSH, and testosterone between the two groups (P < 0.05). The results showed a reduction in the expression of VEGF & HIF1 genes under the effect of resveratrol in the granulosa cells (P = 0.0001). The number of mature oocytes, cleavage rate, fertilization rate, and fertility rate were not significantly different between the two groups (P > 0.05), but the high-quality oocyte rate and high-quality embryo rate were higher in the resveratrol group (P < 0.05).
Based on the results, resveratrol may improve some outcomes of PCOS patients, probably through changing the serum levels of some sex hormones and expression of VEGF & HIF1 genes in the angiogenesis pathway of granulosa cells.
多囊卵巢综合征（PCOS）是育龄妇女最常见的内分泌疾病，使用天然补充剂进行治疗是医生的首要任务，尤其是基于病因途径。因此，本研究旨在描述白藜芦醇对血管生成途径的影响，通过评估 VEGF、HIF1 基因表达和实验室参数来管理 PCOS。
在这项三盲 RCT 中，根据鹿特丹标准，在 ICSI 候选者中确认 PCOS。符合纳入标准的 62 名患者被随机分为两组。所有患者从上次月经周期开始至取卵日每天口服白藜芦醇 800mg 或安慰剂。测量不同激素的血清水平，并通过实时 PCR 定量测定 HIF1 和 VEGF 基因的表达。
在 61 名 PCOS 患者的实验室激素检测中，两组之间 FSH、LH、TSH 和睾酮的平均值存在显著差异（P<0.05）。结果表明，白藜芦醇对颗粒细胞中 VEGF 和 HIF1 基因的表达有抑制作用（P=0.0001）。两组之间成熟卵母细胞数量、卵裂率、受精率和妊娠率无显著差异（P>0.05），但白藜芦醇组的优质卵母细胞率和优质胚胎率更高（P<0.05）。
基于这些结果，白藜芦醇可能通过改变血清中某些性激素的水平和颗粒细胞中 VEGF 和 HIF1 基因的表达来改善 PCOS 患者的某些结局。
